Document is current
Any future updates will be listed below
-
Authors
Lucidarme, Olivier https://orcid.org/0000-0003-0893-3764
Wagner, Mathilde
Gillard, Paul
Kim, Stefano
Bachet, Jean-Baptiste
Rousseau, Benoit
Mazard, Thibault
Louvet, Christophe
Chibaudel, Benoist
Cohen, Romain
Garcia-Larnicol, Marie-Line
Gobert, Aurelien
Henriques, Julie
André, Thierry
-
Funding
Funding for this research was provided by:
Bayer HealthCare (N/A)
- License Information
-
More Information
Article History
Received: 31 July 2019
Accepted: 22 November 2019
First Online: 9 December 2019
Ethics approval and consent to participate
: The TEXCAN study ( Identifier: NCT02699073) was conducted in accordance with the declaration of Helsinki and Good Clinical Practice guidelines. All patients provided a written informed consent. Approval of the protocol was obtained from an independent ethics committee and the French Health Authority.
: “Not applicable”
: Some authors of this manuscript declare relationships with the following companies:- OL: Roche, Bracco, Siemens and Intrasense.- JBB: Amgen, Bayer, Merck Serono, Pierre Fabre, Roche, Sanofi, Servier.- BR: Bayer, Servier, Roche, Novartis, Astellas, Gilead, Abbvie.- TM: ROCHE and AMGEM, Sanofi, Bayer, BMS.- CL: MSD, Roche, Halozyme, Servier, Astra-Zeneca.- BC: Roche, Sanofi, Bayer, Servier, Takeda, Merck, Roche, Amgen.- RC: Servier, Amgen and Sanofi.- TA: Roche/Genentech and Ventana, Baxter, Bayer, Amgen, MSD Oncology, Sanofi, Servier, Novartis Roche/Genentech/ventana, and Bristol-Myers Squibb.- MW, PG, SK, ML G-L, AG and JH have no conflict of interest.
